Keijiro Ueda

Mr. Keijiro Ueda

Kyushu University Hospital, Fukuoka, Japan
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MMMasami Miki
Masami Miki
NFNao Fujimori
Nao Fujimori
KUKeijiro Ueda
Keijiro Ueda
LLLingaku Lee
Lingaku Lee
MMMasatoshi Murakami
Masatoshi Murakami
YOYoshihiro Ogawa
Yoshihiro Ogawa
Although the combination of nanoliposomal irinotecan plus fluorouracil/folinic acid (nal-IRI/FF) exhibited survival benefits in gemcitabine-refractory patients with advanced pancreatic cancer (APC) in the phase III NAPOLI-1 trial, there is limited data on the efficacy and safety of this regimen in real-world settings in Japan. This multicenter, prospective observational study enrolled patients with APC who received nal-IRI/FF after a gemcitabine-based regimen from July 2020 to June 2021. We collected and analyzed clinical data and conducted survival and multivariate analyses. Thirty-one (78%) of the 40 patients had metastases. Nal-IRI/FF was the second-line therapy in 36 patients (90%). The median duration was 3.2 months. The disease control rate was 57%. The median progression-free survival and overall survival (OS) were 4.5 months (95% confidence interval [CI]: 2.8–5.5) and 7.4 months (95% CI: 5.1–10.6), respectively. Common ≥grade 3 toxicities included neutropenia (28%) and fatigue (23%). Fatigue led to treatment discontinuation in 6 out of 10 patients. Multivariate analysis showed that a neutrophil-to-lymphocyte ratio > 4 was a significant risk factor for a short OS (hazard ratio (HR) = 3.08, 95% CI: 1.21–7.85, p = 0.02). In conclusion, nal-IRI/FF is an appropriate treatment option for APC following gemcitabine-containing regimens.

29 February 2024 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MMMasatoshi Murakami
Masatoshi Murakami
NFNao Fujimori
Nao Fujimori
YTYu Takamatsu
Yu Takamatsu
TITetsuhide Ito
Tetsuhide Ito
KMKazuhide Matsumoto
Kazuhide Matsumoto
YOYoshihiro Ogawa
Yoshihiro Ogawa
Streptozocin has been used to treat neuroendocrine tumors in Europe and the USA; however, its actual status in Japan has not been fully clarified owing to the rarity of this disease and the relatively recent approval of streptozocin in Japan. We retrospectively analyzed 53 patients with gastroenteropancreatic neuroendocrine tumors who were treated with streptozocin-based chemotherapy at two Japanese hospitals between January 2004 and June 2023. The overall response and disease control rates were 27.7 and 74.5%, respectively, and the median progression-free survival and overall survival were 7.1 and 20.3 months, respectively. Performance status ≥1 showed a significant negative correlation with progression-free survival, and performance status ≥1 and liver tumor burden ≥25% showed a significant negative correlation with overall survival. No significant differences were observed in the treatment response between pancreatic and gastrointestinal neuroendocrine tumors. No treatment-related serious adverse events were observed; however, 87.7% of patients expressed a decrease in the estimated glomerular filtration rate, which negatively correlated with the duration of streptozocin treatment (r = 0.43, P = 0.0020). In the streptozocin re-administration group (n = 5), no differences were found in efficacy between the initial and second streptozocin treatments. Although streptozocin is a safe, streptozocin-induced renal dysfunction is a dilemma in streptozocin responders. Streptozocin may benefit patients with gastroenteropancreatic neuroendocrine tumors, especially those with a good performance status; however, in some cases, planned streptozocin withdrawal or switching to other drugs should be considered.

30 September 2024 in Clinical Endoscopy
Verified
Journal Article
Open access
AOAkihisa Ohno
Akihisa Ohno
NFNao Fujimori
Nao Fujimori
TKToyoma Kaku
Toyoma Kaku
KMKazuhide Matsumoto
Kazuhide Matsumoto
MMMasatoshi Murakami
Masatoshi Murakami
YOYoshihiro Ogawa
Yoshihiro Ogawa
Background/Aims: Although endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) is performed globally, the procedure remains challenging. Guidewire manipulation is the most difficult step, and there are few reports on the factors associated with unsuccessful guidewire manipulation. This study aimed to assess the significance of the puncture angle on EUS images and identify the most effective guidewire rescue method for patients with unsuccessful guidewire manipulation.Methods: We retrospectively enrolled 115 patients who underwent EUS-HGS between May 2016 and April 2022 at two centers. The puncture angle between the needle and the intrahepatic bile duct was measured through EUS movie records.Results: Guidewire manipulation was unsuccessful in 28 patients. Receiver operating characteristic (ROC) curves identified an optimal puncture angle cutoff value of 85° (cutoff value, 85°; area under the ROC curve, 0.826; sensitivity, 85.7%; specificity, 81.6%). Multivariate analysis demonstrated that a puncture angle <85° was a significant risk factor for unsuccessful guidewire manipulation (odds ratio, 19.8; 95% confidence interval, 6.42–61.5; p<0.001). Among the 28 unsuccessful cases, 24 patients (85.7%) achieved successful guidewire manipulation using various rescue methods.Conclusions: The puncture angle observed on EUS is crucial for guidewire manipulation. A puncture angle of <85° was associated with unsuccessful guidewire manipulation.

1 January 2021 in Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
Verified
Journal Article
Open access
PDF file
CTChikanori Tsutsumi
Chikanori Tsutsumi
TAToshiya Abe
Toshiya Abe
TOTakafumi Okayama
Takafumi Okayama
HKHirotaka Kuga
Hirotaka Kuga
YSYuzo Shimokawa
Yuzo Shimokawa
TNToru Nakano
Toru Nakano
自己免疫性膵炎(AIP)は限局性病変を形成し,膵癌と鑑別困難な症例が存在する.本検討は当院で経験したAIP 34例を対象とし,その臨床学的因子,手術症例の周術期因子を解析した.AIPの5例(14.7%)で膵癌を疑い,手術を施行した.AIPにおいて,多変量解析でCA19-9高値(>37U/mL)(P=0.01),膵外病変なし(P=0.01),EUS-FNA未施行(P<0.01)が手術施行に関わる独立した因子であった.また,単変量解析で 血管浸潤所見(P=0.03)を認めるAIPで有意に手術が施行され,限局性膵腫大(P=0.06)を認めるAIPで手術が施行される傾向にあった.AIPと膵癌の特徴を同時に認める症例ではそれらの鑑別が困難になりやすく,AIPに対する手術を回避するためにはAIPに特徴的な所見を含め,EUS-FNA/FNBの重要性を再認識する必要があると考えられた.

31 January 2025 in International Journal of Gastrointestinal Intervention
Verified
Journal Article
Open access
PDF file
YKYasuhiro Komori
Yasuhiro Komori
AOAkihisa Ohno
Akihisa Ohno
NFNao Fujimori
Nao Fujimori
KMKazuhide Matsumoto
Kazuhide Matsumoto
KUKeijiro Ueda
Keijiro Ueda
YOYoshihiro Ogawa
Yoshihiro Ogawa
Yasuhiro Komori, Akihisa Ohno, Nao Fujimori, Kazuhide Matsumoto, Keijiro Ueda, Kazuki Takeishi, Tomoharu Yoshizumi, and Yoshihiro Ogawa. Int J Gastrointest Interv 2025;14:35-8. https://doi.org/10.18528/ijgii240060

2 April 2026 in Endoscopy
Verified
Journal Article
Open access
PDF file
AFAkito Furuta
Akito Furuta
KUKeijiro Ueda
Keijiro Ueda
KMKazuhide Matsumoto
Kazuhide Matsumoto
MMMasatoshi Murakami
Masatoshi Murakami
NFNao Fujimori
Nao Fujimori
YOYoshihiro Ogawa
Yoshihiro Ogawa
The usefulness of a dedicated hepaticogastrostomy (HGS) plastic stent (TYPE-IT stent; Gadelius Medical, Tokyo, Japan) for endoscopic ultrasound-guided hepaticogastrostomy (EUS-HGS) has been reported [1] [2]. However, to date, no reports have been published on the inward migration of dedicated HGS plastic stents. Here, we report a rare case of post-hepaticojejunostomy, in which a dedicated HGS plastic stent placed from the stomach through the bile duct and into the jejunum had migrated entirely into the bile duct ([Video 1]). A 43-year-old man underwent extrahepatic bile duct resection and hepaticojejunostomy for congenital biliary dilatation. Nine years later, he developed cholangitis and underwent EUS-HGS with the placement of a dedicated HGS plastic stent. An anastomotic stricture was identified between the left hepatic duct and the jejunum ([Fig. 1]). Balloon dilation using an 8-mm balloon was performed every 3 months. In the third session, the notch of the balloon was no longer visible, indicating adequate dilation ([Fig. 2]), and two dedicated HGS plastic stents were placed from the stomach to the jejunum across the dilated anastomotic stricture. Approximately 3 months later, the patient presented with abdominal pain. Abdominal radiography revealed that one of the stents had migrated into the biliary system ([Fig. 3]). An emergency endoscopic procedure was performed, during which a guidewire was advanced through the EUS-HGS tract, and the migrated stent was successfully removed using rotatable grasping forceps ([Fig. 4]). Two double-pigtail plastic stents were placed, and the procedure was completed without complications. The patient recovered without further symptoms, and no additional episodes of stent migration occurred during the follow-up period. This case emphasizes that endoscopists should be cautious about the risk of inward stent migration, despite the use of dedicated HGS plastic stents specifically designed to prevent such complications. Endoscopy_UCTN_Code_CPL_1AL_2AD Article published online: 20 April 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/). Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany